3 Results for "

RMC6236

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "RMC6236" in MCE Product Catalog:

22
22 Cited Publications
Cat. No.: HY-148439
CAS No.: 2765081-21-6
Purity:  99.68%
Synonyms: RMC-6236; RAS-IN-2
Target:  

Ras PERK

Research Areas:  

Cancer

Daraxonrasib (RMC-6236) is an orally active, non-covalent RAS (ON) inhibitor. Daraxonrasib disrupts the interaction of wild-type or mutant RAS proteins with the RAS binding domain of BRAF, with EC50 values ranging from 28-220 nM for wild-type KRAS, NRAS, HRAS, and multiple oncogenic RAS variants. Daraxonrasib inhibits pERK. Daraxonrasib has anti-tumor activity against KRAS mutant tumors .
loading...
    loading...
Cat. No.: HY-148439R
CAS No.: 2765081-21-6
Synonyms: RMC-6236 (Standard); RAS-IN-2 (Standard)
Research Areas:  

Cancer

Daraxonrasib (Standard) is the analytical standard of Daraxonrasib (HY-148439). This product is intended for research and analytical applications. Daraxonrasib (RMC-6236) is an orally active, non-covalent RAS (ON) inhibitor. Daraxonrasib disrupts the interaction of wild-type or mutant RAS proteins with the RAS binding domain of BRAF, with EC50 values ranging from 28-220 nM for wild-type KRAS, NRAS, HRAS, and multiple oncogenic RAS variants. Daraxonrasib inhibits pERK. Daraxonrasib has anti-tumor activity against KRAS mutant tumors .
loading...
    loading...
Cat. No.: HY-148439S
Synonyms: RMC-6236-d5; RAS-IN-2-d5
Research Areas:  

Cancer

Daraxonrasib-d5 (RMC-6236-d5) is the deuterated-labeled Daraxonrasib (HY-148439). Daraxonrasib (RMC-6236) is an orally active, non-covalent RAS (ON) inhibitor. Daraxonrasib disrupts the interaction of wild-type or mutant RAS proteins with the RAS binding domain of BRAF, with EC50 values ranging from 28-220 nM for wild-type KRAS, NRAS, HRAS, and multiple oncogenic RAS variants. Daraxonrasib inhibits pERK. Daraxonrasib has anti-tumor activity against KRAS mutant tumors .
loading...
    loading...